Information Provided By: 
Fly News Breaks for April 1, 2015
DYAX
Apr 1, 2015 | 07:14 EDT
Jefferies raised its price target for Dyax to $31 saying DX-2930 has potential as next standard of care in hereditary angioedema. The firm notes DX-2930 observed significant reductions in HAE attacks compared to placebo in the Phase Ib trial. Going into the data, Jefferies thinks most investors would have been pleased with a 35%-50% reduction in attacks. The company reported the 300 mg and 400 mg dose groups observed 100% and 88% reductions in attacks, respectively. It reiterates a Buy rating on Dyax.
News For DYAX From the Last 2 Days
There are no results for your query DYAX
